Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
Cloux AJ, Aubry D, Heulot M, Widmann C, ElMokh O, Piacente F, Cea M, Nencioni A, Bellotti A, Bouzourène K, Pellegrin M, Mazzolai L, Duchosal MA, Nahimana A. Cloux AJ, et al. Among authors: elmokh o. Oncotarget. 2019 Nov 19;10(62):6723-6738. doi: 10.18632/oncotarget.27336. eCollection 2019 Nov 19. Oncotarget. 2019. PMID: 31803365 Free PMC article.
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
ElMokh O, Matsumoto S, Biniecka P, Bellotti A, Schaeuble K, Piacente F, Gallart-Ayala H, Ivanisevic J, Stamenkovic I, Nencioni A, Nahimana A, Duchosal MA. ElMokh O, et al. Cell Death Dis. 2022 Apr 8;13(4):320. doi: 10.1038/s41419-022-04763-3. Cell Death Dis. 2022. PMID: 35396381 Free PMC article.